Litigation Details for Hikma Pharmaceuticals USA Inc. v. Padagis Israel Pharmaceuticals Limited (D. Del. 2023)

Hikma Pharmaceuticals USA Inc. v. Padagis Israel Pharmaceuticals Limited (D. Del. 2023)

Docket		Date Filed	2023-06-14
Court	District Court, D. Delaware	Date Terminated	2023-12-11
Cause	35:1 Patent Infringement	Assigned To	Gregory B. Williams
Jury Demand	None	Referred To	Sherry R. Fallon
Parties	PADAGIS ISRAEL PHARMACEUTICALS LIMITED
Patents	10,722,510; 10,973,814; 11,135,155; 11,617,713; 11,628,139
Link to Docket	External link to docket

Details for Hikma Pharmaceuticals USA Inc. v. Padagis Israel Pharmaceuticals Limited (D. Del. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-06-14				External link to document

Litigation summary and analysis for: Hikma Pharmaceuticals USA Inc. v. Padagis Israel Pharmaceuticals Limited (D. Del. 2023)

Last updated: July 18, 2026

Hikma v. Padagis (1:23-cv-00654): Litigation summary, claims at issue, and generic entry risks

Hikma Pharmaceuticals USA Inc. v. Padagis Israel Pharmaceuticals Limited (D.N.J., 1:23-cv-00654) is a patent infringement case tied to a Hikma generic drug launch under the Hatch-Waxman framework. The case posture and risk to Padagis’ proposed market entry depend on (i) which Orange Book-listed patents Hikma asserted, (ii) whether Padagis filed a Paragraph IV certification, and (iii) whether any FDA stay/entry timing relief was triggered by an automatic 30-month stay or a settlement-triggered early entry. The docket’s dispositive milestones, the specific asserted patents, and any settlement terms determine whether Hikma’s enforcement materially delays Padagis’ launch or narrows the design-around.

What does Hikma Pharmaceuticals USA Inc. v. Padagis Israel Pharmaceuticals Limited (1:23-cv-00654) allege?

Core theory. Hatch-Waxman suits of this type typically allege that the defendant’s ANDA submission and/or the proposed commercial manufacture, use, sale, offer for sale, or importation of the ANDA product infringes one or more Orange Book-listed patents associated with the reference-listed drug (RLD). The plaintiff’s complaint normally ties infringement to specific claims of the asserted patents and to specific aspects of the ANDA product (e.g., composition/formulation, dosage form, or method-of-use/labeling).

Key infringement targets to confirm in the docket record. The litigation analysis turns on the identity of the asserted patents and claim scope. The practical questions for counsel and business teams are:

• Are asserted patents formulation/composition patents, method-of-use patents, or device/manufacturing process patents?
• Are the asserted claims narrow (e.g., specific ratios, particle size limits, or stability parameters) or broader (e.g., functional claim language)?
• Does the plaintiff assert both independent and dependent claims, and do infringement allegations track claim elements one-to-one?

Which patents were asserted by Hikma in 1:23-cv-00654, and what do those patents cover?

Decision-critical mapping. A defensible litigation strategy requires claim-to-product mapping against the ANDA product description and the patent claim elements. This requires the asserted patent numbers (and their active filing and priority lineage) plus the jurisdiction-specific claim construction approach that the court applies.

What to extract from the filings. The complaint and infringement contentions usually identify:

• Patent numbers asserted
• Patent families and priority/continuation status
• Asserted claims per patent
• Alleged infringement basis tied to ANDA sections (e.g., paragraph IV basis and product characterization)

Without the docket’s asserted-patent list and claim numbers, a precise analysis of strength, likelihood of invalidity arguments, and design-around feasibility cannot be completed.

What is the case timeline for 1:23-cv-00654, including key filings and court actions?

Timing matters for ANDA entry risk. In ANDA litigation, the most business-relevant deadlines include:

• Complaint filing and service
• Defendant’s answer and any Rule 12 motions
• Scheduling order setting discovery and claim construction
• Claim construction (Markman) date
• Summary judgment motions
• Trial date (if scheduled) or dispositive motion outcomes
• Settlement milestone filings (if any)

Why it matters. Each step changes the probability of:

• sustaining an injunction
• securing an early entry (before final resolution)
• narrowing the asserted claims via claim construction
• achieving dismissal based on jurisdictional or statutory grounds

A timeline requires docket-access data (D.N.J. docket entries, dates, and outcomes). Without that, the litigation summary cannot be made complete and accurate.

How does the Hatch-Waxman framework affect Hikma v. Padagis’ 30-month stay and launch timing?

The automatic stay lever. In Paragraph IV cases, the first-filer ANDA can trigger an automatic 30-month stay of FDA approval. The stay can be lifted or extended based on:

• whether the court’s 30-month stay triggers an earlier decision schedule
• final court decision before the end of the stay period
• settlement terms entered into under 21 U.S.C. § 355(j)(5)(D) and (j)(5)(C)
• whether the suit qualifies for stay-related timing under FDA/ANDA rules

Settlement exposure. Many ANDA settlements structure:

• “agreed entry date” tied to patent expiration or to dismissal of certain counts
• partial infringement releases
• covenant-not-to-sue terms for certain patents or product configurations
• stipulated judgment provisions

The practical risk analysis is whether Padagis is protected by any settlement-triggered entry date relief or remains fully stayed pending court outcomes.

What generic entry risks exist for Padagis if Hikma’s asserted patents are method-of-use versus formulation patents?

Method-of-use patents.

• Launch risk concentrates on whether the proposed label infringes claimed method steps.
• Carve-outs, non-infringement labeling, and physician use constraints can materially change infringement risk.
• If claim construction narrows method steps, the defendant’s labeling design can reduce exposure.

Formulation/composition patents.

• Launch risk concentrates on product composition, excipient selection, and manufacturing/process controls.
• Even minor changes can or cannot avoid literal infringement depending on claim language.
• In practice, formulation litigation often hinges on ANDA product characterization and expert testimony.

Process/manufacturing patents.

• Risk focuses on how the drug is made and on whether the ANDA manufacturing description meets claim elements.
• Discovery into manufacturing steps becomes decisive if patents are process-based.

A correct risk profile depends on the asserted patent types, claim language, and the ANDA product description.

How strong is Hikma’s patent estate in this case? An infringement and validity lens

Infringement lens. Strength is driven by:

• whether Hikma asserted patents with clear claim element matching to the ANDA product
• whether infringement relies on a specific physicochemical parameter likely to be directly measured and reproducible (e.g., stability, dissolution, polymorph)
• whether claim scope is broad enough that design-arounds do not evade it

Validity lens. Business teams typically focus on:

• prior art availability and obviousness combinations
• enablement and written description vulnerabilities
• patent eligibility constraints (if asserted claims could be framed as covering natural products or abstract ideas, depending on the patent type)

A strength analysis requires the asserted patents, claim numbers, and the defendant’s invalidity theories in the pleadings and expert disclosures.

What defenses and counters does Padagis typically raise in 1:23-cv-00654?

Standard Hatch-Waxman defenses. Common counters include:

• non-infringement (literal and doctrine of equivalents)
• invalidity (anticipation, obviousness, lack of written description, indefiniteness)
• unenforceability (inequitable conduct)
• procedural defenses (failure to state a claim, lack of standing)
• patent law constraints specific to ANDA cases (e.g., limitation on damages)

Design-around and labeling strategies. Depending on asserted patent types:

• label changes for method-of-use exposure
• formulation tweaks for composition exposure
• manufacturing parameter changes for process exposure

A complete summary requires the docket’s motion filings and the defendant’s contentions.

What settlements, consent judgments, or dismissal outcomes affect the commercial outlook?

In ANDA patent cases, settlement terms can include:

• early resolution that converts litigation into a delayed-entry schedule
• partial dismissals that permit some product configurations to enter
• stipulated judgments or dismissal with prejudice of certain claims
• agreement not to sue until a specific date

A settlement summary must cite the actual settlement date and filed agreement terms from the docket. Without docket access, this cannot be produced accurately.

What is the Orange Book status of the patents at issue in 1:23-cv-00654?

Orange Book link. Hatch-Waxman infringement suits typically involve patents listed in FDA’s Orange Book against the RLD. Orange Book status determines:

• listed expiration dates (including pediatric exclusivity if applicable)
• whether a patent is listed as “drug substance,” “drug product,” or “method of use”
• whether another later-listed patent family could still block approval even if one expires

A correct status section requires the Orange Book patent numbers and their listed expiration dates as of the relevant FDA listing.

How does Hikma v. Padagis compare with other Hikma ANDA patent cases?

Pattern-based risk assessment. Litigation patterns within a plaintiff’s portfolio can indicate:

• whether the plaintiff targets certain patent families consistently (e.g., formulation versus method-of-use)
• whether courts in the district tend to construe certain claim types narrowly or broadly
• whether settlements cluster around particular patent expiration triggers

Comparison requires knowing the asserted patents and the ANDA/RLD context in this specific case.

What is the commercial exposure for Padagis if the court grants an injunction?

If the court finds infringement and validity, the plaintiff can seek injunctive relief prohibiting FDA approval or limiting commercial activity until patent expiration (subject to statutory constraints and bond requirements). Commercial exposure is driven by:

• whether Padagis’ ANDA is first-filer or tied to another filer’s exclusivity
• the expected FDA approval timeline if litigation ends
• product market size and prescribing dependency

Injunction risk is patent-specific and depends on claim scope and validity outcomes.

Key procedural milestones to monitor in D.N.J. for 1:23-cv-00654

For decision-makers, the most important items to track are:

• the court’s claim construction schedule and Markman rulings
• summary judgment outcomes (especially on non-infringement or invalidity)
• any dismissal of counts or narrowing of asserted claims
• any final judgment dates
• any settlement-related docket entries

These determine whether the commercial path is (i) full hold, (ii) narrowed design-around, or (iii) early entry.

---

Key Takeaways

• Hikma v. Padagis (1:23-cv-00654) is a Hatch-Waxman-style patent infringement case where commercial timing and risk hinge on which Orange Book patents Hikma asserted and how the ANDA product maps to those claims.
• Launch exposure depends primarily on whether the asserted patents are method-of-use (labeling-driven), formulation/composition (product-driven), or process (manufacturing-driven).
• The decisive business catalysts are: claim construction outcomes, any summary judgment/dismissal, and any settlement that sets an agreed entry date or narrows asserted counts.
• A complete litigation strength and timeline analysis requires the docket’s asserted patent numbers, claim list, and procedural milestones; those details are not provided in the request.

---

FAQs

1. What triggers FDA approval stays in Paragraph IV Hatch-Waxman cases like Hikma v. Padagis?
2. How do method-of-use versus formulation patents change ANDA design-around strategy?
3. What court events most affect settlement odds in D.N.J. Hatch-Waxman litigation?
4. How does Orange Book “drug product” versus “method of use” listing typically affect infringement theories?
5. What are typical remedies and commercial consequences if a court finds infringement in an ANDA case?

---

References

1. No sources were cited because the request did not include docket text, complaint allegations, asserted patent numbers, or cited Orange Book listings.